Abstract:Graphical and Lay Summary Recombinant adeno‐associated virus (rAAV) is a widely used gene delivery vehicle for human gene therapies, but large‐scale rAAV manufacturing using plasmid transfection and virus infection faces challenges such as cost and inefficiency. This study presents an innovative platform by enhancing previously developed synthetic rAAV producer cell lines. These high‐producing cell lines were integrated with all essential viral components and supplemented with additional copies of the cap gene. They not only generated rAAV with high titers upon induction but also achieved high full‐to‐empty particle ratios by tuning capsid formation through inducer concentrations and induction time profiles. Recombinant adeno‐associated virus (rAAV) is widely used as an in vivo delivery vector for gene therapy. It is used in a very large dose, and the large quantities required for broad applications present manufacturing challenges. We have developed a synthetic biology platform of constructing cell lines integrated with essential viral genes which can be induced to produce rAAV without plasmid transfection or virus transduction. Through iterative design‐construct‐characterization cycles, we have showcased the potential of this synthetic cell production system. Systems characterization of the dynamics of viral transcripts and proteins as well as virus assembly and packaging revealed that the expression level and balance of viral genome and capsid protein are keys to not only the productivity but also the full particle content, an important product quality attribute. Boosting cap gene expression by sequential transfection and integration of multiple copies of the cap gene elevated the rAAV titer to levels on a par with traditional plasmid transfection and virus infection. However, overexpression of the cap gene shifted the balance and kinetics of the genome and capsid. We independently tuned the dynamics of genome amplification and capsid protein synthesis by modulating the induction concentration as well as the time profile, and significantly enhanced full particle content while maintaining a high productivity. This strategy of constructing an inducible stable producer cell line is readily adaptable to rAAV vectors of different serotypes and payloads. It can greatly facilitate scalable production of gene therapy vectors.

Detailed Protocol for the Novel and Scalable Viral Vector Upstream Process for AAV Gene Therapy Manufacturing.

A Streamlined and Standardized Procedure for Generating High-Titer, High-Quality Adeno-Associated Virus Vectors Utilizing a Cell Factory Platform

Engineered CHO cells as a novel AAV production platform for gene therapy delivery

Advanced biomanufacturing and evaluation of adeno-associated virus

High‐yield recombinant adeno‐associated viral vector production by multivariate optimization of bioprocess and transfection conditions

High-Level rAAV Vector Production by rAdV-Mediated Amplification of Small Amounts of Input Vector

Scalable Production of AAV Vectors in Orbitally Shaken HEK293 Cells

AAV Production Everywhere: A Simple, Fast, and Reliable Protocol for In‐house AAV Vector Production Based on Chloroform Extraction

High-Titer Adeno-Associated Viral Vectors from a Rep/Cap Cell Line and Hybrid Shuttle Virus

Process Optimization for the Rapid Production of Adenoviral Vectors for Clinical Trials in a Disposable Bioreactor System.

Molecular design of controllable recombinant adeno‐associated virus (AAV) expression systems for enhanced vector production

Tuning capsid formation dynamics in recombinant adeno‐associated virus producing synthetic cell lines to enhance full particle productivity

Process Improvement of Adeno-Associated Virus Production

A Direct Comparison of rAAV5 Variants Derived from the Baculovirus Expression System Using LC-MS Workflows Demonstrates Key Differences in Overall Production Yield, Product Quality and Vector Efficiency

High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cells

A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy.

A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors.

Critical challenges and advances in recombinant adeno‐associated virus (rAAV) biomanufacturing

Development of Stable Packaging and Producer Cell Lines for the Production of AAV Vectors

Large-Scale Production of Adeno-Associated Viral Vector Serotype-9 Carrying the Human Survival Motor Neuron Gene

Towards a scalable bioprocess for rAAV production using a HeLa stable cell line